Novel Drugs Market Likely to Surpass USD 406.5 Billion by 2035

• 1. Research Methodology and Assumptions
  • 1.1. Definitions
  • 1.2. Research Design and Approach
  • 1.3. Data Collection Methods
  • 1.4. Base Estimates and Calculations
  • 1.5. Forecasting Models
    • 1.5.1. Key Forecast Factors & Impact Analysis
  • 1.6. Secondary Research
    • 1.6.1. Open Sources
    • 1.6.2. Paid Databases
    • 1.6.3. Associations
  • 1.7. Primary Research
    • 1.7.1. Primary Sources
    • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
• 2. Executive Summary
  • 2.1. Global Novel Drugs Market Outlook
    • 2.1.1. Novel Drugs Market Size (Value - US$ Bn), and Forecasts, 2021-2035
    • 2.1.2. Compounded Annual Growth Rate Analysis
    • 2.1.3. Growth Opportunity Analysis
    • 2.1.4. Segmental Share Analysis
    • 2.1.5. Geographical Share Analysis
  • 2.2. Market Analysis and Facts
  • 2.3. Supply-Demand Analysis
  • 2.4. Competitive Benchmarking
  • 2.5. Go-to- Market Strategy
    • 2.5.1. Customer/ End-use Industry Assessment
    • 2.5.2. Growth Opportunity Data, 2026-2035
      • 2.5.2.1. Regional Data
      • 2.5.2.2. Country Data
      • 2.5.2.3. Segmental Data
    • 2.5.3. Identification of Potential Market Spaces
    • 2.5.4. GAP Analysis
    • 2.5.5. Potential Attractive Price Points
    • 2.5.6. Prevailing Market Risks & Challenges
    • 2.5.7. Preferred Sales & Marketing Strategies
    • 2.5.8. Key Recommendations and Analysis
    • 2.5.9. A Way Forward
• 3. Industry Data and Premium Insights
  • 3.1. Global Novel Drugs Industry Overview, 2025
    • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
    • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
    • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
  • 3.2. Supplier Customer Data
  • 3.3. Technology Roadmap and Developments
  • 3.4. Trade Analysis
    • 3.4.1. Import & Export Analysis, 2025
    • 3.4.2. Top Importing Countries
    • 3.4.3. Top Exporting Countries
  • 3.5. Trump Tariff Impact Analysis
    • 3.5.1. Manufacturer
      • 3.5.1.1. Based on the component & Raw material
    • 3.5.2. Supply Chain
    • 3.5.3. End Consumer
  • 3.6. Raw Material Analysis
• 4. Market Overview
  • 4.1. Market Dynamics
    • 4.1.1. Drivers
      • 4.1.1.1. Growing demand for personalized and targeted therapies
      • 4.1.1.2. Advancements in biotechnology and genomics
      • 4.1.1.3. Rising prevalence of chronic and rare diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High R&D and regulatory approval costs
      • 4.1.2.2. Limited accessibility in developing regions
  • 4.2. Key Trend Analysis
    • • 4.2.1.1. Regulatory Framework
    • 4.2.2. Key Regulations, Norms, and Subsidies, by Key Countries
    • 4.2.3. Tariffs and Standards
    • 4.2.4. Impact Analysis of Regulations on the Market
  • 4.3. Value Chain Analysis
    • 4.3.1. Raw Material Suppliers
    • 4.3.2. Manufacturing & Scale-Up
    • 4.3.3. Distributors/ Commercializers
    • 4.3.4. End-users/ Customers
  • 4.4. Porter’s Five Forces Analysis
  • 4.5. PESTEL Analysis
  • 4.6. Global Novel Drugs Market Demand
    • 4.6.1. Historical Market Size - in Value (US$ Bn), 2020-2024
    • 4.6.2. Current and Future Market Size - in Value (US$ Bn), 2026–2035
      • 4.6.2.1. Y-o-Y Growth Trends
      • 4.6.2.2. Absolute $ Opportunity Assessment
• 5. Competition Landscape
  • 5.1. Competition structure
    • 5.1.1. Fragmented v/s consolidated
  • 5.2. Company Share Analysis, 2025
    • 5.2.1. Global Company Market Share
    • 5.2.2. By Region
      • 5.2.2.1. North America
      • 5.2.2.2. Europe
      • 5.2.2.3. Asia Pacific
      • 5.2.2.4. Middle East
      • 5.2.2.5. Africa
      • 5.2.2.6. South America
  • 5.3. Product Comparison Matrix
    • 5.3.1. Specifications
    • 5.3.2. Market Positioning
    • 5.3.3. Pricing
• 6. Global Novel Drugs Market Analysis, By Drug Type
  • 6.1. Key Segment Analysis
  • 6.2. Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, By Drug Type, 2021-2035
    • 6.2.1. Small Molecule Drugs
    • 6.2.2. Biologics
      • 6.2.2.1. Monoclonal Antibodies
      • 6.2.2.2. Antibody-Drug Conjugates (ADCs)
      • 6.2.2.3. Bispecific Antibodies
    • 6.2.3. Cell Therapies
      • 6.2.3.1. CAR-T Cell Therapies
      • 6.2.3.2. NK Cell Therapies
    • 6.2.4. Gene Therapies
    • 6.2.5. RNA-based Therapeutics
      • 6.2.5.1. mRNA Therapeutics
      • 6.2.5.2. siRNA Therapeutics
      • 6.2.5.3. ASO (Antisense Oligonucleotides)
    • 6.2.6. Peptide Therapeutics
    • 6.2.7. Protein Therapeutics
    • 6.2.8. Others
• 7. Global Novel Drugs Market Analysis, By Therapeutic Area
  • 7.1. Key Segment Analysis
  • 7.2. Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, By Cargo Type, 2021-2035
    • 7.2.1. Oncology
      • 7.2.1.1. Solid Tumors
      • 7.2.1.2. Hematological Malignancies
    • 7.2.2. Immunology & Autoimmune Disorders
    • 7.2.3. Cardiovascular Diseases
    • 7.2.4. Central Nervous System Disorders
      • 7.2.4.1. Neurodegenerative Diseases
      • 7.2.4.2. Psychiatric Disorders
    • 7.2.5. Metabolic Disorders
      • 7.2.5.1. Diabetes
      • 7.2.5.2. Obesity
      • 7.2.5.3. Others
    • 7.2.6. Rare Diseases (Orphan Drugs)
    • 7.2.7. Infectious Diseases
    • 7.2.8. Respiratory Disorders
    • 7.2.9. Others
• 8. Global Novel Drugs Market Analysis and Forecasts,By Mechanism of Action
  • 8.1. Key Findings
  • 8.2. Novel Drugs Market Size (Value - US$ Mn), Analysis, and Forecasts, By Mechanism of Action, 2021-2035
    • 8.2.1. Targeted Therapy
    • 8.2.2. Immunotherapy
    • 8.2.3. Gene Editing (CRISPR-based)
    • 8.2.4. Enzyme Replacement Therapy
    • 8.2.5. Signal Transduction Modulators
    • 8.2.6. Epigenetic Modulators
    • 8.2.7. Others
• 9. Global Novel Drugs Market Analysis and Forecasts, By Route of Administration
  • 9.1. Key Findings
  • 9.2. Novel Drugs Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Route of Administration Method, 2021-2035
    • 9.2.1. Oral
    • 9.2.2. Injectable
      • 9.2.2.1. Subcutaneous
      • 9.2.2.2. Intramuscular
      • 9.2.2.3. Intravenous
      • 9.2.2.4. Others
    • 9.2.3. Transdermal Patches
    • 9.2.4. Inhalation
    • 9.2.5. Topical
• 10. Global Novel Drugs Market Analysis and Forecasts, By Technology Platform
  • 10.1. Key Findings
  • 10.2. Novel Drugs Market Size (Value - US$ Mn), Analysis, and Forecasts, By Technology Platform, 2021-2035
    • 10.2.1. Recombinant DNA Technology
    • 10.2.2. Hybridoma Technology
    • 10.2.3. CRISPR/Cas9
    • 10.2.4. Viral Vector-based
    • 10.2.5. Non-viral Vector-based
    • 10.2.6. Nanoparticle-based Delivery
    • 10.2.7. Lipid Nanoparticle (LNP) Technology
    • 10.2.8. Others
• 11. Global Novel Drugs Market Analysis and Forecasts, By Drug Classification
  • 11.1. Key Findings
  • 11.2. Novel Drugs Market Size (Value - US$ Mn), Analysis, and Forecasts, By Drug Classification, 2021-2035
    • 11.2.1. First-in-Class
    • 11.2.2. Best-in-Class
    • 11.2.3. Me-too Drugs
    • 11.2.4. Biosimilars/Biobetters
• 12. Global Novel Drugs Market Analysis and Forecasts, By End-users
  • 12.1. Key Findings
  • 12.2. Novel Drugs Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
    • 12.2.1. Healthcare Facilities
      • 12.2.1.1. Inpatient Treatment
      • 12.2.1.2. Outpatient Treatment
      • 12.2.1.3. Chronic Disease Management
      • 12.2.1.4. Acute Care
      • 12.2.1.5. Chemotherapy
      • 12.2.1.6. Immunotherapy
      • 12.2.1.7. Others
    • 12.2.2. Research & Academic Institutions
      • 12.2.2.1. Drug Discovery Research
      • 12.2.2.2. Clinical Research
      • 12.2.2.3. Preclinical Studies
      • 12.2.2.4. Biomarker Development
      • 12.2.2.5. Others
    • 12.2.3. Pharmaceutical & Biotechnology Companies
      • 12.2.3.1. Commercial Production
      • 12.2.3.2. Clinical Trial Supply
      • 12.2.3.3. Clinical Development
      • 12.2.3.4. Scale-up Production
      • 12.2.3.5. Others
    • 12.2.4. Home Healthcare
      • 12.2.4.1. Self-administration
      • 12.2.4.2. Remote Patient Monitoring
      • 12.2.4.3. Palliative Care
      • 12.2.4.4. Others
    • 12.2.5. Other End-users
• 13. Global Novel Drugs Market Analysis and Forecasts, by Region
  • 13.1. Key Findings
  • 13.2. Novel Drugs Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
    • 13.2.1. North America
    • 13.2.2. Europe
    • 13.2.3. Asia Pacific
    • 13.2.4. Middle East
    • 13.2.5. Africa
    • 13.2.6. South America
• 14. North America Novel Drugs Market Analysis
  • 14.1. Key Segment Analysis
  • 14.2. Regional Snapshot
  • 14.3. North America Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 14.3.1. Drug Type
    • 14.3.2. Therapeutic Area
    • 14.3.3. Mechanism of Action
    • 14.3.4. Route of Administration
    • 14.3.5. Technology Platform
    • 14.3.6. Drug Classification
    • 14.3.7. End-Users
    • 14.3.8. Country
      • 14.3.8.1. USA
      • 14.3.8.2. Canada
      • 14.3.8.3. Mexico
  • 14.4. USA Novel Drugs Market
    • 14.4.1. Country Segmental Analysis
    • 14.4.2. Drug Type
    • 14.4.3. Therapeutic Area
    • 14.4.4. Mechanism of Action
    • 14.4.5. Route of Administration
    • 14.4.6. Technology Platform
    • 14.4.7. Drug Classification
    • 14.4.8. End-Users
  • 14.5. Canada Novel Drugs Market
    • 14.5.1. Country Segmental Analysis
    • 14.5.2. Drug Type
    • 14.5.3. Therapeutic Area
    • 14.5.4. Mechanism of Action
    • 14.5.5. Route of Administration
    • 14.5.6. Technology Platform
    • 14.5.7. Drug Classification
    • 14.5.8. End-Users
  • 14.6. Mexico Novel Drugs Market
    • 14.6.1. Country Segmental Analysis
    • 14.6.2. Drug Type
    • 14.6.3. Therapeutic Area
    • 14.6.4. Mechanism of Action
    • 14.6.5. Route of Administration
    • 14.6.6. Technology Platform
    • 14.6.7. Drug Classification
    • 14.6.8. End-Users
• 15. Europe Novel Drugs Market Analysis
  • 15.1. Key Segment Analysis
  • 15.2. Regional Snapshot
  • 15.3. Europe Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 15.3.1. Drug Type
    • 15.3.2. Therapeutic Area
    • 15.3.3. Mechanism of Action
    • 15.3.4. Route of Administration
    • 15.3.5. Technology Platform
    • 15.3.6. Drug Classification
    • 15.3.7. End-Users
    • 15.3.8. Country
      • 15.3.8.1. Germany
      • 15.3.8.2. United Kingdom
      • 15.3.8.3. France
      • 15.3.8.4. Italy
      • 15.3.8.5. Spain
      • 15.3.8.6. Netherlands
      • 15.3.8.7. Nordic Countries
      • 15.3.8.8. Poland
      • 15.3.8.9. Russia & CIS
      • 15.3.8.10. Rest of Europe
  • 15.4. Germany Novel Drugs Market
    • 15.4.1. Country Segmental Analysis
    • 15.4.2. Drug Type
    • 15.4.3. Therapeutic Area
    • 15.4.4. Mechanism of Action
    • 15.4.5. Route of Administration
    • 15.4.6. Technology Platform
    • 15.4.7. Drug Classification
    • 15.4.8. End-Users
  • 15.5. United Kingdom Novel Drugs Market
    • 15.5.1. Country Segmental Analysis
    • 15.5.2. Drug Type
    • 15.5.3. Therapeutic Area
    • 15.5.4. Mechanism of Action
    • 15.5.5. Route of Administration
    • 15.5.6. Technology Platform
    • 15.5.7. Drug Classification
    • 15.5.8. End-Users
  • 15.6. France Novel Drugs Market
    • 15.6.1. Country Segmental Analysis
    • 15.6.2. Drug Type
    • 15.6.3. Therapeutic Area
    • 15.6.4. Mechanism of Action
    • 15.6.5. Route of Administration
    • 15.6.6. Technology Platform
    • 15.6.7. Drug Classification
    • 15.6.8. End-Users
  • 15.7. Italy Novel Drugs Market
    • 15.7.1. Country Segmental Analysis
    • 15.7.2. Drug Type
    • 15.7.3. Therapeutic Area
    • 15.7.4. Mechanism of Action
    • 15.7.5. Route of Administration
    • 15.7.6. Technology Platform
    • 15.7.7. Drug Classification
    • 15.7.8. End-Users
  • 15.8. Spain Novel Drugs Market
    • 15.8.1. Country Segmental Analysis
    • 15.8.2. Drug Type
    • 15.8.3. Therapeutic Area
    • 15.8.4. Mechanism of Action
    • 15.8.5. Route of Administration
    • 15.8.6. Technology Platform
    • 15.8.7. Drug Classification
    • 15.8.8. End-Users
  • 15.9. Netherlands Novel Drugs Market
    • 15.9.1. Country Segmental Analysis
    • 15.9.2. Drug Type
    • 15.9.3. Therapeutic Area
    • 15.9.4. Mechanism of Action
    • 15.9.5. Route of Administration
    • 15.9.6. Technology Platform
    • 15.9.7. Drug Classification
    • 15.9.8. End-Users
  • 15.10. Nordic Countries Novel Drugs Market
    • 15.10.1. Country Segmental Analysis
    • 15.10.2. Drug Type
    • 15.10.3. Therapeutic Area
    • 15.10.4. Mechanism of Action
    • 15.10.5. Route of Administration
    • 15.10.6. Technology Platform
    • 15.10.7. Drug Classification
    • 15.10.8. End-Users
  • 15.11. Poland Novel Drugs Market
    • 15.11.1. Country Segmental Analysis
    • 15.11.2. Drug Type
    • 15.11.3. Therapeutic Area
    • 15.11.4. Mechanism of Action
    • 15.11.5. Route of Administration
    • 15.11.6. Technology Platform
    • 15.11.7. Drug Classification
    • 15.11.8. End-Users
  • 15.12. Russia & CIS Novel Drugs Market
    • 15.12.1. Country Segmental Analysis
    • 15.12.2. Drug Type
    • 15.12.3. Therapeutic Area
    • 15.12.4. Mechanism of Action
    • 15.12.5. Route of Administration
    • 15.12.6. Technology Platform
    • 15.12.7. Drug Classification
    • 15.12.8. End-Users
  • 15.13. Rest of Europe Novel Drugs Market
    • 15.13.1. Country Segmental Analysis
    • 15.13.2. Drug Type
    • 15.13.3. Therapeutic Area
    • 15.13.4. Mechanism of Action
    • 15.13.5. Route of Administration
    • 15.13.6. Technology Platform
    • 15.13.7. Drug Classification
    • 15.13.8. End-Users
• 16. Asia Pacific Novel Drugs Market Analysis
  • 16.1. Key Segment Analysis
  • 16.2. Regional Snapshot
  • 16.3. Asia Pacific Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 16.3.1. Drug Type
    • 16.3.2. Therapeutic Area
    • 16.3.3. Mechanism of Action
    • 16.3.4. Route of Administration
    • 16.3.5. Technology Platform
    • 16.3.6. Drug Classification
    • 16.3.7. End-Users
    • 16.3.8. Country
      • 16.3.8.1. China
      • 16.3.8.2. India
      • 16.3.8.3. Japan
      • 16.3.8.4. South Korea
      • 16.3.8.5. Australia and New Zealand
      • 16.3.8.6. Indonesia
      • 16.3.8.7. Malaysia
      • 16.3.8.8. Thailand
      • 16.3.8.9. Vietnam
      • 16.3.8.10. Rest of Asia Pacific
  • 16.4. China Novel Drugs Market
    • 16.4.1. Country Segmental Analysis
    • 16.4.2. Drug Type
    • 16.4.3. Therapeutic Area
    • 16.4.4. Mechanism of Action
    • 16.4.5. Route of Administration
    • 16.4.6. Technology Platform
    • 16.4.7. Drug Classification
    • 16.4.8. End-Users
  • 16.5. India Novel Drugs Market
    • 16.5.1. Country Segmental Analysis
    • 16.5.2. Drug Type
    • 16.5.3. Therapeutic Area
    • 16.5.4. Mechanism of Action
    • 16.5.5. Route of Administration
    • 16.5.6. Technology Platform
    • 16.5.7. Drug Classification
    • 16.5.8. End-Users
  • 16.6. Japan Novel Drugs Market
    • 16.6.1. Country Segmental Analysis
    • 16.6.2. Drug Type
    • 16.6.3. Therapeutic Area
    • 16.6.4. Mechanism of Action
    • 16.6.5. Route of Administration
    • 16.6.6. Technology Platform
    • 16.6.7. Drug Classification
    • 16.6.8. End-Users
  • 16.7. South Korea Novel Drugs Market
    • 16.7.1. Country Segmental Analysis
    • 16.7.2. Drug Type
    • 16.7.3. Therapeutic Area
    • 16.7.4. Mechanism of Action
    • 16.7.5. Route of Administration
    • 16.7.6. Technology Platform
    • 16.7.7. Drug Classification
    • 16.7.8. End-Users
  • 16.8. Australia and New Zealand Novel Drugs Market
    • 16.8.1. Country Segmental Analysis
    • 16.8.2. Drug Type
    • 16.8.3. Therapeutic Area
    • 16.8.4. Mechanism of Action
    • 16.8.5. Route of Administration
    • 16.8.6. Technology Platform
    • 16.8.7. Drug Classification
    • 16.8.8. End-Users
  • 16.9. Indonesia Novel Drugs Market
    • 16.9.1. Country Segmental Analysis
    • 16.9.2. Drug Type
    • 16.9.3. Therapeutic Area
    • 16.9.4. Mechanism of Action
    • 16.9.5. Route of Administration
    • 16.9.6. Technology Platform
    • 16.9.7. Drug Classification
    • 16.9.8. End-Users
  • 16.10. Malaysia Novel Drugs Market
    • 16.10.1. Country Segmental Analysis
    • 16.10.2. Drug Type
    • 16.10.3. Therapeutic Area
    • 16.10.4. Mechanism of Action
    • 16.10.5. Route of Administration
    • 16.10.6. Technology Platform
    • 16.10.7. Drug Classification
    • 16.10.8. End-Users
  • 16.11. Thailand Novel Drugs Market
    • 16.11.1. Country Segmental Analysis
    • 16.11.2. Drug Type
    • 16.11.3. Therapeutic Area
    • 16.11.4. Mechanism of Action
    • 16.11.5. Route of Administration
    • 16.11.6. Technology Platform
    • 16.11.7. Drug Classification
    • 16.11.8. End-Users
  • 16.12. Vietnam Novel Drugs Market
    • 16.12.1. Country Segmental Analysis
    • 16.12.2. Drug Type
    • 16.12.3. Therapeutic Area
    • 16.12.4. Mechanism of Action
    • 16.12.5. Route of Administration
    • 16.12.6. Technology Platform
    • 16.12.7. Drug Classification
    • 16.12.8. End-Users
  • 16.13. Rest of Asia Pacific Novel Drugs Market
    • 16.13.1. Country Segmental Analysis
    • 16.13.2. Drug Type
    • 16.13.3. Therapeutic Area
    • 16.13.4. Mechanism of Action
    • 16.13.5. Route of Administration
    • 16.13.6. Technology Platform
    • 16.13.7. Drug Classification
    • 16.13.8. End-Users
• 17. Middle East Novel Drugs Market Analysis
  • 17.1. Key Segment Analysis
  • 17.2. Regional Snapshot
  • 17.3. Middle East Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 17.3.1. Drug Type
    • 17.3.2. Therapeutic Area
    • 17.3.3. Mechanism of Action
    • 17.3.4. Route of Administration
    • 17.3.5. Technology Platform
    • 17.3.6. Drug Classification
    • 17.3.7. End-Users
    • 17.3.8. Country
      • 17.3.8.1. Turkey
      • 17.3.8.2. UAE
      • 17.3.8.3. Saudi Arabia
      • 17.3.8.4. Israel
      • 17.3.8.5. Rest of Middle East
  • 17.4. Turkey Novel Drugs Market
    • 17.4.1. Country Segmental Analysis
    • 17.4.2. Drug Type
    • 17.4.3. Therapeutic Area
    • 17.4.4. Mechanism of Action
    • 17.4.5. Route of Administration
    • 17.4.6. Technology Platform
    • 17.4.7. Drug Classification
    • 17.4.8. End-Users
  • 17.5. UAE Novel Drugs Market
    • 17.5.1. Country Segmental Analysis
    • 17.5.2. Drug Type
    • 17.5.3. Therapeutic Area
    • 17.5.4. Mechanism of Action
    • 17.5.5. Route of Administration
    • 17.5.6. Technology Platform
    • 17.5.7. Drug Classification
    • 17.5.8. End-Users
  • 17.6. Saudi Arabia Novel Drugs Market
    • 17.6.1. Country Segmental Analysis
    • 17.6.2. Drug Type
    • 17.6.3. Therapeutic Area
    • 17.6.4. Mechanism of Action
    • 17.6.5. Route of Administration
    • 17.6.6. Technology Platform
    • 17.6.7. Drug Classification
    • 17.6.8. End-Users
  • 17.7. Israel Novel Drugs Market
    • 17.7.1. Country Segmental Analysis
    • 17.7.2. Drug Type
    • 17.7.3. Therapeutic Area
    • 17.7.4. Mechanism of Action
    • 17.7.5. Route of Administration
    • 17.7.6. Technology Platform
    • 17.7.7. Drug Classification
    • 17.7.8. End-Users
  • 17.8. Rest of Middle East Novel Drugs Market
    • 17.8.1. Country Segmental Analysis
    • 17.8.2. Drug Type
    • 17.8.3. Therapeutic Area
    • 17.8.4. Mechanism of Action
    • 17.8.5. Route of Administration
    • 17.8.6. Technology Platform
    • 17.8.7. Drug Classification
    • 17.8.8. End-Users
• 18. Africa Novel Drugs Market Analysis
  • 18.1. Key Segment Analysis
  • 18.2. Regional Snapshot
  • 18.3. Africa Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 18.3.1. Drug Type
    • 18.3.2. Therapeutic Area
    • 18.3.3. Mechanism of Action
    • 18.3.4. Route of Administration
    • 18.3.5. Technology Platform
    • 18.3.6. Drug Classification
    • 18.3.7. End-Users
    • 18.3.8. Country
      • 18.3.8.1. South Africa
      • 18.3.8.2. Egypt
      • 18.3.8.3. Nigeria
      • 18.3.8.4. Algeria
      • 18.3.8.5. Rest of Africa
  • 18.4. South Africa Novel Drugs Market
    • 18.4.1. Country Segmental Analysis
    • 18.4.2. Drug Type
    • 18.4.3. Therapeutic Area
    • 18.4.4. Mechanism of Action
    • 18.4.5. Route of Administration
    • 18.4.6. Technology Platform
    • 18.4.7. Drug Classification
    • 18.4.8. End-Users
  • 18.5. Egypt Novel Drugs Market
    • 18.5.1. Country Segmental Analysis
    • 18.5.2. Drug Type
    • 18.5.3. Therapeutic Area
    • 18.5.4. Mechanism of Action
    • 18.5.5. Route of Administration
    • 18.5.6. Technology Platform
    • 18.5.7. Drug Classification
    • 18.5.8. End-Users
  • 18.6. Nigeria Novel Drugs Market
    • 18.6.1. Country Segmental Analysis
    • 18.6.2. Drug Type
    • 18.6.3. Therapeutic Area
    • 18.6.4. Mechanism of Action
    • 18.6.5. Route of Administration
    • 18.6.6. Technology Platform
    • 18.6.7. Drug Classification
    • 18.6.8. End-Users
  • 18.7. Algeria Novel Drugs Market
    • 18.7.1. Country Segmental Analysis
    • 18.7.2. Drug Type
    • 18.7.3. Therapeutic Area
    • 18.7.4. Mechanism of Action
    • 18.7.5. Route of Administration
    • 18.7.6. Technology Platform
    • 18.7.7. Drug Classification
    • 18.7.8. End-Users
  • 18.8. Rest of Africa Novel Drugs Market
    • 18.8.1. Country Segmental Analysis
    • 18.8.2. Drug Type
    • 18.8.3. Therapeutic Area
    • 18.8.4. Mechanism of Action
    • 18.8.5. Route of Administration
    • 18.8.6. Technology Platform
    • 18.8.7. Drug Classification
    • 18.8.8. End-Users
• 19. South America Novel Drugs Market Analysis
  • 19.1. Key Segment Analysis
  • 19.2. Regional Snapshot
  • 19.3. South America Novel Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
    • 19.3.1. Drug Type
    • 19.3.2. Therapeutic Area
    • 19.3.3. Mechanism of Action
    • 19.3.4. Route of Administration
    • 19.3.5. Technology Platform
    • 19.3.6. Drug Classification
    • 19.3.7. End-Users
    • 19.3.8. Country
      • 19.3.8.1. Brazil
      • 19.3.8.2. Argentina
      • 19.3.8.3. Rest of South America
  • 19.4. Brazil Novel Drugs Market
    • 19.4.1. Country Segmental Analysis
    • 19.4.2. Drug Type
    • 19.4.3. Therapeutic Area
    • 19.4.4. Mechanism of Action
    • 19.4.5. Route of Administration
    • 19.4.6. Technology Platform
    • 19.4.7. Drug Classification
    • 19.4.8. End-Users
  • 19.5. Argentina Novel Drugs Market
    • 19.5.1. Country Segmental Analysis
    • 19.5.2. Drug Type
    • 19.5.3. Therapeutic Area
    • 19.5.4. Mechanism of Action
    • 19.5.5. Route of Administration
    • 19.5.6. Technology Platform
    • 19.5.7. Drug Classification
    • 19.5.8. End-Users
  • 19.6. Rest of South America Novel Drugs Market
    • 19.6.1. Country Segmental Analysis
    • 19.6.2. Drug Type
    • 19.6.3. Therapeutic Area
    • 19.6.4. Mechanism of Action
    • 19.6.5. Route of Administration
    • 19.6.6. Technology Platform
    • 19.6.7. Drug Classification
    • 19.6.8. End-Users
• 20. Key Players/ Company Profile
  • 20.1. AbbVie Inc.
    • 20.1.1. Company Details/ Overview
    • 20.1.2. Company Financials
    • 20.1.3. Key Customers and Competitors
    • 20.1.4. Business/ Industry Portfolio
    • 20.1.5. Product Portfolio/ Specification Details
    • 20.1.6. Pricing Data
    • 20.1.7. Strategic Overview
    • 20.1.8. Recent Developments
  • 20.2. Amgen Inc.
  • 20.3. AstraZeneca PLC
  • 20.4. Bayer AG
  • 20.5. Biogen Inc.
  • 20.6. BioNTech SE
  • 20.7. Boehringer Ingelheim
  • 20.8. Bristol Myers Squibb
  • 20.9. Eli Lilly and Company
  • 20.10. Gilead Sciences, Inc.
  • 20.11. GlaxoSmithKline plc (GSK)
  • 20.12. Johnson & Johnson
  • 20.13. Merck & Co., Inc.
  • 20.14. Moderna, Inc.
  • 20.15. Novartis AG
  • 20.16. Novo Nordisk A/S
  • 20.17. Pfizer Inc.
  • 20.18. Regeneron Pharmaceuticals, Inc.
  • 20.19. Roche Holding AG
  • 20.20. Sanofi S.A.
  • 20.21. Takeda Pharmaceutical Company Limited
  • 20.22. Vertex Pharmaceuticals Incorporated
  • 20.23. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography